Skip to main content
Top
Published in:

Open Access 18-06-2024 | Venous Thrombosis | Case Report

Unprovoked venous thromboembolism recurrence and arterial embolism revealing lung cancer: a case report

Authors: Maria-Cristina Glodeanu, Victoria Mutruc, Camelia-Maria Apetrei, Manuela Ursaru, Laurentiu Sorodoc, Catalina Lionte

Published in: Thrombosis Journal | Issue 1/2024

Login to get access

Abstract

The link between venous thromboembolism (VTE) and cancer is well known. VTE could be the initial sign of an occult malignancy. There are more diagnoses of cancer after an unprovoked VTE compared to a provoked VTE, with a reported prevalence between 4.5% and 5.6% over 12 months, within the first 6 months of VTE diagnosis. There are no recommended guidelines and scores yet adopted in clinical practice, but many studies support occult cancer screening in unprovoked VTE patients. We report the case of a patient with a history of unprovoked pulmonary embolism (PE) diagnosed with bronchopulmonary neoplasm in an advanced stage one year after the thromboembolic event. When the cancer was first diagnosed, the patient’s condition was already serious, being too late for the adoption of measures meant to decrease the risk of mortality and increase the duration of survival. We wanted to emphasize the importance of occult cancer screening in patients with unprovoked VTE and the fact that early cancer diagnosis reduces the risk of cancer progression, decreasing mortality and morbidity related to it.
Literature
1.
go back to reference Patel SS, Tao D, McMurry HS, Shatzel JJ. Screening for occult cancer after unprovoked venous thromboembolism: assessing the current literature and future directions. Eur J Haematol. 2022;110:24–31.CrossRefPubMedPubMedCentral Patel SS, Tao D, McMurry HS, Shatzel JJ. Screening for occult cancer after unprovoked venous thromboembolism: assessing the current literature and future directions. Eur J Haematol. 2022;110:24–31.CrossRefPubMedPubMedCentral
2.
go back to reference Saba HI, Khalil FK, Morelli GA, Foulis PR. Thromboembolism preceding cancer: a correlation study. Am J Hematol. 2003;72:109–14.CrossRefPubMed Saba HI, Khalil FK, Morelli GA, Foulis PR. Thromboembolism preceding cancer: a correlation study. Am J Hematol. 2003;72:109–14.CrossRefPubMed
3.
go back to reference Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, et al. Screening for Occult Cancer in unprovoked venous thromboembolism. NEJM. 2015;373:697–704.CrossRefPubMed Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, et al. Screening for Occult Cancer in unprovoked venous thromboembolism. NEJM. 2015;373:697–704.CrossRefPubMed
4.
go back to reference Robin P, Le Roux PY, Planquette B, Accassat S, Roy PM, Couturaud F, et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol. 2016;17(2):193–9.CrossRefPubMed Robin P, Le Roux PY, Planquette B, Accassat S, Roy PM, Couturaud F, et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol. 2016;17(2):193–9.CrossRefPubMed
5.
go back to reference Ryma Ihaddadene, Corsi DJ, Lazo-Langner A, Sudeep Shivakumar, Zarychanski R, Tagalakis V, et al. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood. 2016;127:2035–7.CrossRefPubMed Ryma Ihaddadene, Corsi DJ, Lazo-Langner A, Sudeep Shivakumar, Zarychanski R, Tagalakis V, et al. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood. 2016;127:2035–7.CrossRefPubMed
6.
go back to reference van Es N, Gal GL, Otten H-M, Robin P, Piccioli A, Lécumberri R, et al. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. BMJ Open. 2017;7:e015562.CrossRefPubMedPubMedCentral van Es N, Gal GL, Otten H-M, Robin P, Piccioli A, Lécumberri R, et al. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. BMJ Open. 2017;7:e015562.CrossRefPubMedPubMedCentral
10.
go back to reference Mulder FI, Carrier M, van Doormaal F, Robin P, Otten HM, Salaun PY, et al. Results from an individual patient data meta-analysis. J Thromb Haemost. 2020;18(10):2622–8.CrossRefPubMedPubMedCentral Mulder FI, Carrier M, van Doormaal F, Robin P, Otten HM, Salaun PY, et al. Results from an individual patient data meta-analysis. J Thromb Haemost. 2020;18(10):2622–8.CrossRefPubMedPubMedCentral
11.
go back to reference Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781–9.CrossRefPubMedPubMedCentral Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781–9.CrossRefPubMedPubMedCentral
12.
go back to reference Prandoni P, Bernardi E, Dalla Valle F, Visonà A, Tropeano PF, Bova C, et al. Extensive computed Tomography versus Limited Screening for detection of Occult Cancer in unprovoked venous thromboembolism: a Multicenter, Controlled, Randomized Clinical Trial. Seminars in thrombosis and hemostasis. (Print). 2016;4 2:884–90. Prandoni P, Bernardi E, Dalla Valle F, Visonà A, Tropeano PF, Bova C, et al. Extensive computed Tomography versus Limited Screening for detection of Occult Cancer in unprovoked venous thromboembolism: a Multicenter, Controlled, Randomized Clinical Trial. Seminars in thrombosis and hemostasis. (Print). 2016;4 2:884–90.
13.
go back to reference Gran OV, Brækkan SK, Paulsen B, Skille H, Rosendaal FR, Hansen J-B. Occult cancer‐related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism. JTH. 2017;15:1361–7.PubMed Gran OV, Brækkan SK, Paulsen B, Skille H, Rosendaal FR, Hansen J-B. Occult cancer‐related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism. JTH. 2017;15:1361–7.PubMed
14.
go back to reference Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. JTH. 2017;15:2076–9.PubMed Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, Carrier M. Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. JTH. 2017;15:2076–9.PubMed
15.
go back to reference Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost. 2014;40(2):163–71.CrossRefPubMed Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost. 2014;40(2):163–71.CrossRefPubMed
16.
go back to reference Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller SC, Cortes-Hernandez J, Connors JM, Kanthi Y, Krumholz HM, Middeldorp S, Falanga A, Cushman M, Goldhaber SZ, Garcia DA, Bikdeli B. Direct oral anticoagulants vs Vitamin K Antagonists in patients with antiphospholipid syndromes: Meta-Analysis of Randomized trials. J Am Coll Cardiol. 2023;81(1):16–30.CrossRefPubMed Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller SC, Cortes-Hernandez J, Connors JM, Kanthi Y, Krumholz HM, Middeldorp S, Falanga A, Cushman M, Goldhaber SZ, Garcia DA, Bikdeli B. Direct oral anticoagulants vs Vitamin K Antagonists in patients with antiphospholipid syndromes: Meta-Analysis of Randomized trials. J Am Coll Cardiol. 2023;81(1):16–30.CrossRefPubMed
17.
go back to reference Blom JW, Malignancies. Prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715.CrossRefPubMed Blom JW, Malignancies. Prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715.CrossRefPubMed
20.
go back to reference Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J. International Initiative on thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–47.CrossRefPubMedPubMedCentral Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J. International Initiative on thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–47.CrossRefPubMedPubMedCentral
21.
go back to reference Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with Cancer. JACC: CardioOncology. 2021;3. Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with Cancer. JACC: CardioOncology. 2021;3.
22.
go back to reference Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. JTH. 2008;6:1289–95.PubMed Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. JTH. 2008;6:1289–95.PubMed
Metadata
Title
Unprovoked venous thromboembolism recurrence and arterial embolism revealing lung cancer: a case report
Authors
Maria-Cristina Glodeanu
Victoria Mutruc
Camelia-Maria Apetrei
Manuela Ursaru
Laurentiu Sorodoc
Catalina Lionte
Publication date
18-06-2024
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2024
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-024-00622-7

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more